ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 106 filers reported holding ASCENDIS PHARMA A/S in Q4 2018. The put-call ratio across all filers is 0.16 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $16,972,000 | -46.4% | 144,194 | -71.5% | 0.65% | -48.6% |
| Q4 2018 | $31,644,000 | +39.6% | 505,098 | +57.8% | 1.27% | +56.0% |
| Q3 2018 | $22,675,000 | -29.3% | 320,000 | -33.7% | 0.81% | -28.0% |
| Q2 2018 | $32,094,000 | +1.7% | 482,467 | 0.0% | 1.13% | +3.1% |
| Q1 2018 | $31,553,000 | -0.2% | 482,467 | -38.9% | 1.09% | -12.1% |
| Q4 2017 | $31,607,000 | +2.6% | 789,000 | -7.2% | 1.24% | -10.4% |
| Q3 2017 | $30,813,000 | +164.6% | 850,000 | +102.6% | 1.39% | +123.5% |
| Q2 2017 | $11,644,000 | -55.2% | 419,453 | -54.9% | 0.62% | -38.1% |
| Q1 2017 | $26,018,000 | +22.4% | 929,226 | -11.5% | 1.00% | +14.8% |
| Q4 2016 | $21,252,000 | +5659.3% | 1,050,000 | +4933.8% | 0.87% | +7183.3% |
| Q2 2015 | $369,000 | -89.4% | 20,859 | -89.6% | 0.01% | -89.3% |
| Q1 2015 | $3,470,000 | – | 200,000 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 2,046,832 | $240,912,000 | 24.02% |
| RA Capital Management | 4,132,442 | $486,388,000 | 20.97% |
| VHCP Management II, LLC | 504,210 | $59,346,000 | 17.36% |
| Ghost Tree Capital, LLC | 385,000 | $45,315,000 | 11.84% |
| Sofinnova Investments, Inc. | 998,538 | $117,528,000 | 11.33% |
| Foresite Capital Management IV, LLC | 245,424 | $28,886,000 | 10.38% |
| Avoro Capital Advisors LLC | 1,795,000 | $211,272,000 | 9.14% |
| Orbimed Advisors | 3,970,673 | $467,348,000 | 7.24% |
| Eventide Asset Management | 1,698,648 | $199,931,000 | 6.88% |
| Foresite Capital Management III, LLC | 204,088 | $24,021,000 | 6.25% |